- Home
- QSI vs AUTL Comparison
QSI vs AUTL Comparison
Compare QSI & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QSI | AUTL |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United Kingdom |
| Employees | 145 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.8M | 431.2M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | QSI | AUTL |
|---|---|---|
| Price | $0.74 | $1.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $1.00 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 3.1M | 1.7M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | N/A | $85.73 |
| Revenue Next Year | $618.07 | $70.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $0.72 | $1.11 |
| 52 Week High | $3.10 | $2.70 |
Technical Indicators
Market Signals| Indicator | QSI | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 34.20 | 48.12 |
| Support Level | N/A | $1.27 |
| Resistance Level | $1.11 | $1.52 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 12.24 | 66.20 |
Price Performance
Historical ComparisonAbout QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.